IBD — primarily Crohn’s disease and ulcerative colitis — has no known cause, though many believe it occurs when microbes within the intestine trigger an immune response in predisposed individuals.
The EU-funded project, titled “IBD: Proteases Offer New Targets for Drug Discover,” is examining matrix metalloproteases enzymes, which break down other proteins. The researchers’ new insight could help focus treatment studies on various inhibitors or agonists of digestive bacterial proteases.
More Articles on Gastroenterology:
University Hospital in London Hosting Live Endoscopy Course
Irritable Bowel Syndrome Drug Eluxadoline Could Relieve IBS Symptoms
Mailed Invitations May Increase Screenings for Noninvasive Tests
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.